Concepedia

Haitian Quan

HQ

Statistics

Publications

24

Citations

1.6K

H-Index

19

Active since

2007

Affiliations

Shanghai Institute of Materia Medica(Current)

Chinese Academy of Sciences

University of Chinese Academy of Sciences

University of Science and Technology Liaoning

Wenzhou University

Haitian Quan is an author at Shanghai Institute of Materia Medica specializing in oncology, pharmacology, and medicine.

ORCID

Publications per year

2007–2021

24

Publications

24

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>

Shu Tian, Haitian Quan, Chengying Xie et al. · Cancer Science · 2011 · 521 citations · Full text

, , +17

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Chengying Xie, Xiaozhe Wan, Haitian Quan et al. · Cancer Science · 2018 · 371 citations · Full text

, , +17

RON confers lapatinib resistance in HER2-positive breast cancer cells

Quanren Wang, Haitian Quan, Jie Zhao et al. · Cancer Letters · 2013 · 69 citations

, , +14

Aberrant intracellular metabolism of T‐ <scp>DM</scp> 1 confers T‐ <scp>DM</scp> 1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells

Hongbin Wang, Wenqian Wang, Yongping Xu et al. · Cancer Science · 2017 · 68 citations · Full text

, , +15

<scp>STAT</scp>3 activation confers trastuzumab‐emtansine (T‐<scp>DM</scp>1) resistance in <scp>HER</scp>2‐positive breast cancer

Lei Wang, Quanren Wang, Mingzhao Gao et al. · Cancer Science · 2018 · 56 citations · Full text

, , +17

1–5 of 24